Table 1. CRA and cell expansion results... | American Society of Hematology

Table 1.

CRA and cell expansion results after IVS with unmodified and ubiquitinated pp65-VV

	% Cytotoxicity to pp65 MCE
HLA, donor UPN, and IVS VV-pp65	A2_495-503	B7_417-426	Expansion, fold
*A^0201**
001			67
Unmodified	66	—
Ubiquitinated	91	—
002			7
Unmodified	28	—
Ubiquitinated	41	—
003			190
Unmodified	40	—
Ubiquitinated	70	—
004			151
Unmodified	66	—
Ubiquitinated	76	—
*B^0702**
005			23
Unmodified	—	46
Ubiquitinated	—	75
006			10
Unmodified	—	74
Ubiquitinated	—	79
007			65
Unmodified	—	42
Ubiquitinated	—	72
008			340
Unmodified	—	41
Ubiquitinated	—	55

	% Cytotoxicity to pp65 MCE
HLA, donor UPN, and IVS VV-pp65	A2_495-503	B7_417-426	Expansion, fold
*A^0201**
001			67
Unmodified	66	—
Ubiquitinated	91	—
002			7
Unmodified	28	—
Ubiquitinated	41	—
003			190
Unmodified	40	—
Ubiquitinated	70	—
004			151
Unmodified	66	—
Ubiquitinated	76	—
*B^0702**
005			23
Unmodified	—	46
Ubiquitinated	—	75
006			10
Unmodified	—	74
Ubiquitinated	—	79
007			65
Unmodified	—	42
Ubiquitinated	—	72
008			340
Unmodified	—	41
Ubiquitinated	—	55

CRA, described in “Materials and methods,” was performed after 7 to 12 days IVS with pp65-VV (unmodified) or UbRpp65-VV (ubiquitinated) for each CMV-positive donor. The lysis percentages to autologous LCL targets, pulsed with pp65_495-503 for HLA A^*0201 donors or with pp65_417-426 for HLA A^*0702 donors, are shown at E/T 20, except for donor 004 reported at E/T 5. In the last column, the highest cell expansion obtained after unmodified or ubiquitinated VV-pp65 IVS is shown for each donor. — indicates not applicable.

View Large

This Feature Is Available To Subscribers Only